Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze RPRX Royalty Pharma plc. Please read: https://finlab.finance/en/setup?stock=RPRX

No install, open FinLab Studio

RPRX

Royalty Pharma plc Healthcare As of 2026-07-31 Updated daily after market close

strong quality, premium valuation.

2 active signals

52-week adjusted-price high Top-quintile 6-month momentum

This page refreshes daily after the close. Add Royalty Pharma plc to your watchlist to track signal changes on your next visit.

Is Royalty Pharma plc a buy? Fundamentals and valuation first

Quality is top-tier. Operating margin ranks above roughly 95% of the liquid US common-stock universe. TTM ROE is about 12.0%.
Valuation is expensive. TTM P/E is in the 84th percentile, above most peers.
Recent volatility is comparatively low. 60-day annualized volatility is in the 22th percentile. Average 20-day dollar volume is about $156.1M.
Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

9 historical occurrences (since 2022-08-16)

120 days after: historical avg +18.8%

20-day +3.64%

60-day +8.04%

120-day +18.8%

20-day

60-day

120-day

Win

77.8%

75%

85.7%

Sample

Median

+3.17%

+6.74%

+19.87%

Excess

+3.2%

+7.23%

+12.04%

Beat mkt rate

66.7%

75%

71.4%

Over 7 occurrences, 120-day forward avg gained 18.8%, beat the market by 12.04 pts; win rate 85.7%.

Top-quintile 6-month momentum

Active · now 88.08510638297872%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

11 historical occurrences (since 2022-04-08)

120 days after: historical avg +1.18%

20-day +0.78%

60-day +4.88%

120-day +1.18%

20-day

60-day

120-day

Win

63.6%

80%

50%

Sample

Median

+2.64%

+2.01%

+0.41%

Excess

+1.2%

+2.7%

-2.46%

Beat mkt rate

63.6%

60%

50%

Over 8 occurrences, 120-day forward avg gained 1.18%, lagged the market by 2.46 pts; win rate 50%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

0-20 +33%

20-40 +45.1%

40-60 Insufficient data

60-80 Insufficient data Now

80-100 -3.6%

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20	290	+33%	+30%	100%	+18.5%
20-40	76	+45.1%	+46.7%	100%	+25%
40-60	0	Insufficient data
60-80 You are here	8	Insufficient data
80-100	69	-3.6%	-3.6%	29%	-30.1%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 33.01, placing it in the 64.4 own-history percentile, inside the 60-80 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation

Momentum

Cheap (own-history bottom third)

Middle

Expensive (own-history top third)

60-day momentum up

+12.7%

Win rate 86.3% Excess +3.5%

262d

Now

+38.4%

Win rate 100% Excess +29.7%

64d

-4.1%

Win rate 13.3% Excess -17.5%

45d

60-day momentum down

+14.2%

Win rate 64.4% Excess +8.8%

160d

Insufficient data
(0d)

+1.1%

Win rate 75% Excess -15.8%

32d

Currently in “Middle × 60-day momentum up”: across 64 historical days, 120-day forward avg gained 38.4%, win rate 100%, beat the market by 29.7%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

10 times historically; 60-day forward avg +2.62%, win rate 50%, beating the market by -1.02 pts on average.

Method and limits

Returns use us_price:adj_close, adjusted for splits and dividends where available.
Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.